New hope for myeloma patients who have run out of options
NCT ID NCT07348393
Summary
This study is testing a new combination of three drugs to control multiple myeloma that has returned or stopped responding to standard treatments. It will involve about 70 adults whose cancer has progressed despite prior therapy, including specific drugs like lenalidomide. The main goal is to see how long the treatment can keep the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Saint-Antoine Hospital
Paris, 75012, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.